Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients by Ezzikouri, Sayeh et al.
Genetic Variation in the Interleukin-28B Gene Is
Associated with Spontaneous Clearance and Progression
of Hepatitis C Virus in Moroccan Patients
Sayeh Ezzikouri1*, Rhimou Alaoui2, Khadija Rebbani1, Ikram Brahim1, Fatima-Zohra Fakhir1,
Salwa Nadir2, Helmut Diepolder3, Salim I. Khakoo4, Mark Thursz5, Soumaya Benjelloun1*
1 Virology Unit, Viral Hepatitis Laboratory, Pasteur Institute of Morocco, Casablanca, Morocco, 2 Service de Me´decine B, CHU Ibn Rochd, Casablanca, Morocco, 3 Ludwig-
Maximilians-Universita¨t Mu¨nchen, Marchioninistrasse, Mu¨nchen, Germany, 4University of Southampton, Tremona Road, Southampton, United Kingdom, 5Department of
Hepatology, Division of Medicine, Imperial College, London, United Kingdom
Abstract
Background: Genetic variation in the IL28B gene has been strongly associated with treatment outcomes, spontaneous
clearance and progression of the hepatitis C virus infection (HCV). The aim of the present study was to investigate the role of
polymorphisms at this locus with progression and outcome of HCV infection in a Moroccan population.
Methods: We analyzed a cohort of 438 individuals among them 232 patients with persistent HCV infection, of whom 115
patients had mild chronic hepatitis and 117 had advanced liver disease (cirrhosis and hepatocellular carcinoma), 68
individuals who had naturally cleared HCV and 138 healthy subjects. The IL28B SNPs rs12979860 and rs8099917 were
genotyped using a TaqMan 59 allelic discrimination assay.
Results: The protective rs12979860-C and rs8099917-T alleles were more common in subjects with spontaneous clearance
(77.9% vs 55.2%; p = 0.00001 and 95.6% vs 83.2%; p = 0.0025, respectively). Individuals with clearance were 4.69 (95% CI,
1.99–11.07) times more likely to have the C/C genotype for rs12979860 polymorphism (p= 0.0017) and 3.55 (95% CI, 0.19–
66.89) times more likely to have the T/T genotype at rs8099917. Patients with advanced liver disease carried the rs12979860-
T/T genotype more frequently than patients with mild chronic hepatitis C (OR= 1.89; 95% CI, 0.99–3.61; p = 0.0532) and this
risk was even more pronounced when we compared them with healthy controls (OR= 4.27; 95% CI, 2.08–8.76; p = 0.0005).
The rs8099917-G allele was also associated with advanced liver disease (OR= 2.34; 95% CI, 1.40–3.93; p = 0.0100).
Conclusions: In the Moroccan population, polymorphisms near the IL28B gene play a role both in spontaneous clearance
and progression of HCV infection.
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Introduction
Infection with hepatitis C virus (HCV) is a worldwide health
problem, with more than 170 million individuals infected. This
infection results in a chronic active hepatitis in more than 80% of
the infected patients, of whom 20–30% develop progressive
cirrhosis and hepatocellular carcinoma (HCC), conversely only
about 10–20% of infected people spontaneously eliminate the
virus [1]. In Morocco, the prevalence of anti-HCV antibody in the
general population is estimated to be 1.1% [2]. More than 70% of
HCV infections in Morocco are genotype 1b, which is the most
common genotype in Western North Africa [3]. Therapy with
pegintereron-alpha (PegIFN-a) and ribavirin (RVB) is successful in
only about 50% of patients infected with genotype 1 [4]. Viral and
host factors have been associated with the differences in HCV
clearance or persistence, and previous studies have demonstrated
that a strong host immune response against HCV favours viral
clearance [5,6]. Ethnic differences in the frequency of virus
elimination suggest an involvement of host genetic variation in
spontaneous clearance [7]. Four independent genome-wide
association studies (GWAS) have recently identified several single
nucleotide polymorphisms (SNPs) around the interleukin-28B
(IL28B) gene, located on chromosome 19q13, coding for IFN-l3,
that are strongly associated with treatment outcome and
spontaneous HCV clearance [8,9,10,11]. The two strongest
genetic predictors for spontaneous HCV and treatment clearance
were SNPs rs12979860 and rs8099917 [8,9,11]. The rs12979860
SNP lies 3 kb upstream of the IL28B gene whereas rs8099917 is
located 8.9 kb from the IFNl3-encoding transcript 39 end in the
intergenic region between IFNl2 and IFNl3. These polymor-
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phisms exhibit substantial ethnic diversity in their frequency
[8,9,11].
Because of its particular geographical location, between the
Mediterranean sea, the Atlantic Ocean, and the Sahara desert,
Moroccan populations has a dual Berberic and Arabic ethnicity.
They show limited genetic diversity as the Arabs and Berbers are
closely related [12]. Although the association between IL28B
polymorphisms and the outcome of HCV infection is well
recognised, they have not been studied in Moroccan or in other
Maghreb populations. Furthermore there are relatively few studies
that have investigated whether this genetic variant also influence
the progression of chronic HCV infection [13,14,15,16,17].
In this study, we tested the hypothesis that the SNPs rs12979860
and rs8099917, and their combined effect, are associated with
spontaneous clearance and progression of HCV infection in a
Moroccan population, in addition to treatment response. To test
this hypothesis, we used a prospectively followed up Moroccan
cohort that was well characterized in terms of the natural outcome
of HCV infection, the stage of disease and treatment response.
Materials and Methods
Patients
To participate in the study, written informed consent for genetic
testing including IL28B polymorphisms and other potential
markers was obtained from all individuals. Each participant was
interviewed and completed a structured questionnaire to elicit
demographic data and selected risk factors. The study protocol
was evaluated and approved by the ethics Committee of the
Faculty of Medicine of Casablanca and the study was conducted in
accordance with the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the institution’s human
research committee. Both plasma and peripheral blood mononu-
clear cells (PBMCs) were stored for all patients. A cohort consisting
of 438 Moroccan individuals were enrolled in this study at the
Medical Center of Biology at the Pasteur Institute of Morocco and
Service of Medicine B CHU Ibn Rochd hospital, Casablanca from
January 2010 to October 2012. Two hundred and thirty-two
subjects had persistent HCV infection. One hundred and eight
were male and 124 female. All were persistently positive for anti-
hepatitis C virus (anti-HCV) antibodies and HCV RNA by a
quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) for at least six months. Patients were stratified into
two groups according to fibrosis stage as determined by histology.
One hundred and fifteen patients had mild chronic hepatitis C
(mCHC) (patients with F0 and F1) and 117 patients had advanced
liver disease (AdLD) (57 cirrhosis without HCC and 60 cirrhosis
with HCC). Sixty-eight individuals (male cases, n = 21 and female
cases, n = 47) had spontaneously resolved HCV infection. All were
positive for HCV-specific antibodies and negative for HCV RNA
in patient’s sera by qRT-PCR from at least two measurements
more than 6 months apart. Controls consisted of 138 unrelated
healthy subjects of mixed Berberic and Arabic ethnicity, who were
negative for viral hepatitis markers and had normal serum levels of
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST). All patients were HBsAg and HIV negative. Serological
markers for HBsAg, anti-HCV and anti-HIV were tested with
commercially available kits (Axsym, Abbott Diagnostics, Wiesba-
den-Delkenheim, Germany and Genscreen Ag/Ab HIV Ultra,
Biorad, Marnes La Coquette, France). Plasma HCV-RNA was
measured using COBAS AmpliPrep/COBAS TaqMan (Roche
Diagnostics, Germany). Hepatitis C virus genotypes were deter-
mined by sequencing as described previously [3].
Isolation of Genomic DNA and SNPs Genotyping
Genomic DNA was isolated from PBMC using QIAamp DNA
Blood Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Genomic DNA concentration was
assessed using a NanoVue plus spectrophotometer (GE Health-
care, US). Genotyping for the SNP rs12979860 was performed by
means of a TaqMan 59 allelic discrimination assay. The primers
used were forward 59-TGCCTGTCGTGTACTGAACCA-39
and reverse 59-GAGCGCGGAGTGCAATTC-39. The sequences
of the Taqman probes were TGGTTCGCGCCTTC and
CTGGTTCACGCCTTC. The probes were labelled with the
fluorescent dyes VIC and FAM, respectively. The PCR reaction
was carried out in a total volume of 25ml, containing 20 ng of
genomic DNA, with the following amplification protocol: pre-
incubation at 50uC for 2 min and then 95uC for 10 min, followed
by 40 cycles of denaturation at 95uC for 15 s, and annealing/
extension at 60uC for 1 min. The genotype of each sample was
attributed by the SDS 1.1 software for allelic discrimination
(ABI7000, Applied Biosystems, Foster City, CA, USA). Most of the
genotypes were confirmed by single base sequencing of PCR
products using primers Forward 59-GCTTATCGCATACGGC-
TAGGC-39 and reverse 59-TTCCCATACACCCGTTCCTGT-
39, PCR was carried out in a final volume of 25ml, containing
50 ng of genomic DNA, 20 pmol/ml of each primer, 0.5 unit of
GoTaq DNA polymerase (Promega, France), 200mM of each
dNTP and 1.5 mM MgCl2. The resulting 367-bp PCR product
was purified using the Exonuclease I/Shrimp Alkaline Phospha-
tase (GE Healthcare, US) and sequenced using BigDye Termina-
tor version 3.1 Cycle Sequencing kit (Applied Biosystems, Foster
City, CA, USA) and an ABI PRISM 3130 DNA automated
sequencer (Applied Biosystems, Foster City, CA, USA). Sequenc-
ing data were analyzed using SeqScape v2.5 software (Applied
Biosystems, Foster City, CA, USA). The SNP rs8099917 was
genotyped using a predesigned TaqMan SNP Genotyping Assay
(Applied Biosystems; assay ID C_11710096_10). For 20% of the
samples, genotyping was repeated for quality control. The results
had 100% concordance.
Statistical Analysis
Continuous variables are presented as mean 6 standard
deviation or median (range) while categorical variables are
expressed as frequencies (%). Differences between continuous
variables were analyzed using the Mann-Whitney U test, whilst
those between categorical variables were evaluated using the
Pearson chi-square test or Fisher’s exact test. Departures from
Hardy-Weinberg equilibrium were determined by comparing the
observed genotype frequencies with expected genotype frequencies
in all groups calculated using observed allele frequencies by chi-
square G test ‘‘Goodness of Fit’’ with 1 degree of freedom using
website http://ihg2.helmholtz-muenchen.de/ihg/snps.html. The
existence of differences in allelic and genotypic frequencies
between different groups was assessed by means of chi-square test
for linear trend when appropriate and calculating the odds ratio
(OR) with the 95% confidence intervals (CI). Multiple logistic
regression models were used to asses whether IL28B rs12979860
C/T and IL28B rs8099917 T/G polymorphisms could be
considered a predictor of spontaneous resolution and the risk of
advanced liver disease. A P value of ,0.05 was used as the
criterion for statistical significance. All the statistical analyses were
performed using Statistical Package for Social Sciences (SPSS)
program (version 10.0, SPSS Inc., Chicago, IL, USA).
Impact of IL28B Polymorphisms on HCV Infection
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Results
The demographic data, biochemical features, viral load, viral
genotype, and clinical features of our cohort groups are
summarized in Table 1. Two hundred and thirty-two patients
with HCV persistent infection with a mean age of 63.66612.26
years [range, 20–90 years], 68 individuals with spontaneous
resolution with a mean age of 57.77615.64 years [range, 17–83
years] and 138 normal controls with a mean age of 56.26610.57
years [range, 25–85 years] were enrolled in this study. There were
no statistically significant differences in the distributions of sex and
age between all groups (p.0.05). The mean serum ALT and AST
levels was significantly higher in the persistently infected group
compared with resolved and control groups (p,0.05). With regard
to the viral genotypes, 70% of the patients were infected with viral
genotype 1 and 30% of patients with genotype 2 (Table 1). This
result is consistent with a recently published report showing the
predominance of genotype 1 in Moroccan patients [3].
To estimate the frequencies of the IL28B genotypes in Morocco
population, the SNPs rs12979860 and rs8099917 were genotyped
in healthy controls (Table 2). Overall, the genotype distribution at
the rs12979860-C/T locus was as follows: 64 (46%) individuals
were C/C homozygous, 59 (43%) were heterozygous and 15
(11%) were T/T homozygotes. At the SNP rs8099917-T/G, the
distribution was T/T 80%, T/G 20%, G/G 0%. The allele
frequency at the rs12979860 SNP was as follows: 68% for the C
allele (95% confidence interval (CI) 63%) and 90% 61.69% for
the T allele for the rs8099917 SNP. The genotype distributions at
both SNPs were in Hardy-Weinberg equilibrium in the healthy
control (for the SNP rs12979860, p = 0.845 and for the SNP
rs8099917, p = 0.363).
In order to analyze the impact of polymorphisms of IL28B gene
in the Moroccan population, we genotyped rs12979860 (C/T) and
rs8099917 (T/G) polymorphisms in patients with persistent HCV
infection and individuals who had spontaneously cleared the virus
(Table 2). Subjects with the rs12979860 C/C genotype cleared
HCV infection more often those with the rs12979860-T/T
genotype (OR=4.69; 95% CI, 1.99–11.07; p= 0.0017) or the
rs12979860-CT genotype (OR=2.46 (95% CI, 1.29–4.70;
p = 0.0543) (Table 2). Interestingly, when individuals were
stratified according to their rs12979860 genotypes (C/C vs. C/
T+T/T), the C/C genotype was overrepresented in the resolved
group (66.2%) compared to the persistent HCV infection group
(38.4%) (p= 361025). The rs12979860 C/C genotype was
associated with resolution of HCV in both males and females.
These results were confirmed by analysis of the linked SNP
rs8099917 (Table 2). Genotype distributions were in Hardy-
Weinberg equilibrium in both groups (p = 0.345 and 1.00,
respectively). 158 of 232 patients (68.1%) with persistent infection
were homozygous for T/T, 70 (30.2%) were heterozygous (T/G)
and 4 (1.7%) homozygous (G/G), reflecting a T-allele frequency of
83.2%. In individuals with spontaneous clearance the T/T
genotype was found in 62 (91.2%) individuals and the G/T
genotype in 6 (8.8%). The frequency of the T allele (95.6%) was
significantly greater among individuals with HCV clearance as
compared to those with persistent infection (83.2%) (p= 0.0025)
(Table 2). The IL28B T/T genotype was found less frequently in
the persistent group compared to spontaneous resolvers (68.1% vs.
91.2%, p= 461025). Interestingly, when patients with persistent
HCV infection were stratified by their viral genotypes, the
frequencies of the C/T+T/T genotypes in patients infected with
genotype 1 (67.3%) was more prevalent than in patients with
genotype 2 (53.5%) (p = 0.0432). Whereas, for the SNP rs8099917,
the frequency of G/T+G/G in patients with genotype 1 was
39.8% which was higher than in those infected with genotype 2
(27.9%) (p = 0.0641). This is consistent with a differential effect of
the IL-28B polymorphisms on the outcome of genotype 1 versus
genotype 2 HCV infection.
To test the association between the SNP rs12979860 and the
progression of HCV disease, we genotyped this polymorphism in
117 patients with advanced liver disease (patients with cirrhosis
and/or HCC) and compared them with 115 patients with mCHC
(Table 3). The frequency of the T/T genotype was significantly
overrepresented in advanced liver disease patients compared with
mCHC (p= 0.0366) a trend even more pronounced when we
compared these frequencies with those of healthy controls (11%,
p= 261025, Table 3). The frequency of the rs12979860-T allele
Table 1. Demographic and clinical characteristics of the study subjects.
Persistent infection (n=232) Spontaneous clearance (n =68) Healthy controls (N =138)
Mean age 6 SD, y 63.66612.26 57.77615.64 56.26610.57
Gender (%)
Male 48 31 48
Female 52 69 52
Alanine aminotransferase (IU/L) 80.38649.41 31.03614.90 26.5369.41
Aspartate aminotransferase (IU/L) 75.59650.81 29.03617.08 25.2169.37
Mean Bilirubin (mmol/L) 26.77610.20 10.0762.70
Mean creatinin (mmol/l) 112.576105.15 77.28626.23
Median Viral Load (IU/ml) 835817 [2030–2.8.108]
Viral genotypes (%)
Genotype 1 70
Genotype 2 30
mCHC{ 115
Advanced Liver Disease (AdLD)* 117
{Patients with mild chronic hepatitis C.
*including patient with liver cirrhosis and hepatocellular carcinoma.
doi:10.1371/journal.pone.0054793.t001
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in advanced liver disease (50%) was also significantly higher than
in patients with mCHC (39.6%) (p = 0.0238). In multivariate
logistic regression analysis the association of the rs12979860-T/T
genotype with advanced liver disease compared with mCHC
revealed an OR of 1.89 (CI, 0.99–3.61; p= 0.0532) after
adjustment for age, sex and viral genotype.
We found a similar effect for the SNP rs8099917. In
multivariate logistic regression analysis after adjustment for age
and sex we found that the genotypes T/G+G/G were higher in
those with advanced liver disease as compared to mCHC (42%
versus 21%, respectively) (p = 0.0002) (Table 3). Taking the T/T
genotype as the reference, the OR and 95% CI for the T/G and
Table 2. Effect of IL28B polymorphisms on the outcomes of HCV infection.
Healthy controls
Subjects with
persistence
Subjects with
spontaneous
clearance
Subjects with
persistence vs. Subjects
with spontaneous
clearance OR (95% CI) P-value¥
rs12979860 n= 276 n= 464 n = 136
C allele 0.68060.03 0.55260.026 0.77960.040 C vs T 2.87 (1.84–4.48) 0.00001
T allele 0.32060.03 0.44860.026 0.22160.040
n = 138 n= 232 n = 68
C/C 64 (46.4%) 89 (38.4%) 45 (66.2%) C/C vs T/T 4.69 (1.99–11.07 0.0017
C/T 59 (42.7%) 78 (33.6%) 16 (23.5%) C/C vs C/T 2.46 (1.29–4.70) 0.0543
T/T 15 (10.9%) 65 (28%) 7 (10.3%) C/C vs C/T and T/T 3.14 (1.78–5.55 0.0004
rs8099917 n= 276 n= 464 n = 136
T allele 0.90260.017 0.83260.017 0.95660.017 T vs G 4.38 (1.86–10.28) 0.0025
G allele 0.09860.017 0.16860.017 0.04460.017
n = 138 n= 232 n = 68
T/T 111 (80.4%) 158 (68.1%) 62 (91.2%) T/T vs T/G 4.58 (1.89–11.08) 0.0029
T/G 27 (19.6%) 70 (30.2%) 6 (8.8%) T/T vs G/G 3.55 (0.19–66.89) 0.2110
G/G 0 (0%) 4 (1.7%) 0 (0%) T/T vs T/G and G/G 4.84 (2.00–11.69) 0.0017
¥Bonferroni correction was applied.
doi:10.1371/journal.pone.0054793.t002
Table 3. Effect of IL28B polymorphisms on the progression of HCV infection.
Healthy
controls
(N =138)
mCHC group
(n=115)
HCV-AdLD
group
(n =117)
mCHC vs. AdLD
OR (95% CI) P-value¥
Healthy controls
vs. AdLD
OR (95% CI) P-value¥
Mean age 6 SD 56.26610.57 60.58614.21 66.5369.26 0.0039
Male/Female 66/72 44/71 64/53 0.0130
Genotype 1 - 65% 72% 0.4360
Genotype 2 - 35% 28%
rs12979860
C/C 64 (46.4%) 51 (44.3%) 38 (32.5%) 1.00 1.00
C/T 59 (42.7%) 37 (32.2%) 41 (35%) 1.49 (0.81–2.74) 0.2025 1.17 (0.66–2.06) 0.5855
T/T 15 (10.9%) 27 (23.5%) 38 (32.5%) 1.89 (0.99–3.61) 0.0532 4.27 (2.08–8.76) 0.0005
C allele 0.68060.03 0.60460.037 0.50060.037 1.00 1.00
T allele 0.32060.03 0.39660.037 0.50060.037 1.53 (1.06–2.21) 0.0238 2.10 (1.47–3.01) 0.0005
rs8099917
T/T 111 (80.4%) 91 (79.1%) 68 (58.1%) 1.00 1.00
T/G 27 (19.6%) 23 (20%) 46 (39.3%) 2.68 (1.48-4.83) 0.0091 2.78 (1.58–4.88) 0.0029
G/G 0 (0%) 1 (0.9%) 3 (2.6%) 4.00 (0.41–39.44) 0.1991 11.94 (0.58–223.97) 0.2898
T allele 0.90260.017 0.89160.020 0.77860.025 1.00 1.00
G allele 0.09860.017 0.10960.020 0.22260.025 2.34 (1.40–3.93) 0.0100 2.63 (1.59–4.36) 0.0011
*Adjusted for age, gender and viral genotype.
¥Bonferroni correction was applied.
doi:10.1371/journal.pone.0054793.t003
Impact of IL28B Polymorphisms on HCV Infection
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e54793
G/G genotypes presence in the advanced versus mild groups were
2.6861.4824.83 and 4.0060.41239.44 respectively (Table 3).
Data for clearance following PegIFN-a plus RVB treatment
were available in 41 patients. For the SNP rs12979860, there is a
statistical difference (p= 0.035) was observed for the distribution of
the genotype C/C [75%, n= 6] and genotypes C/T and T/T
[25%, n=2] between responders and non-responders (genotype
C/C [33%, n=11] and genotypes C/T and T/T [67%, n= 22],
Fisher’s exact test). Furthermore the rs8099917 polymorphism was
associated with SVR. In responders the frequency of patients with
T/T genotype (80%) was higher than in non-responders (60%)
(OR=0.46, 95% CI 0.22–1.09; p = 0.019).
The analysis of the combination of SNPs rs12979860 with
rs8099917 showed that patients with persistent infection were 8.27
(95% CI, 1.90–36.11; p = 0.0011) times more likely to have the
rs12979860-T/T/rs8099917-T/G genotypes (13.80% vs 2.94% in
resolved group) and 4.68 (95% CI, 0.25–88.85) fold to have
rs12979860-TT/rs8099917-GG genotypes (1.72% vs none in
resolved group) but did not reach the significance (p = 0.155) when
compared to rs12979860-C/C/rs8099917-T/T carriers.
Therefore, we hypothesized that an increased risk of progression
towards advanced liver disease could be detected when unfavour-
able alleles are combined in a given patient. Consequently, the
SNP-SNP combination of rs12979860 with rs8099917 was
examined. We found that the rs12979860-T/T/rs8099917-T/G
genotype was present in 19.6% of the advanced group versus 6.9%
in mCHC (p= 0.0035), conferring an OR of 3.70 (95% CI, 1.49–
9.20, p= 0.0035) for advanced liver disease. Additionally the
frequency for patients with rs12979860-T/T/rs8099917-G/G
genotypes was 2.6% in the advanced group vs 0.9% in mCHC
conferring a 3.87-fold increased risk for advanced liver disease
compared to rs12979860-C/C/rs8099917-T/T carriers.
Discussion
The ability of the virus to persist within a host’s attributed to its
efficient ability to evade the adaptive and innate components of
the host’s immune system. In addition, a small number of specific
host polymorphisms have been correlated with spontaneous HCV
clearance [18]. The SNPs near the IL28B gene on chromosome 19
coding for type III IFN-l3 have recently been reported to be
associated with clearance and treatment response in HCV [8,19].
First, we analyzed the IL28B polymorphisms in the 138 healthy
subjects. The rs12979860-C allele frequency observed in the
Moroccan population (68%) was similar to that reported in the
Egyptian population (67%) [20] and in the Italian population
(68%) [13,21] but was significantly higher than those observed
within the sub-Saharan African populations (23.1–54.8%) [19].
However, the C allele frequency remains much lower than the
highest frequencies found in Eastern Asian (91–100%) and in
Oceanian populations (100%) [19]. The frequency of the
favourable T allele of the rs8099917 SNPwas 90% amongst
Moroccan subjects, which is similar to frequencies reported in
African (93%) and European (83%) populations but was higher
than those observed in a population with Mexican ancestry (69%)
[22]. Thus ethnic differences in the IL28B gene polymorphisms
may explain, at least in part, the different outcomes rates of HCV
infection in different ethnic groups. For this reason, we examined
the genetic variation in the IL28B gene and the natural clearance
of HCV infection in the Moroccan population. Our results
demonstrate that the rs12979860- C/C genotype is strongly
associated with spontaneous eradication of the virus in the
Maghreban populations. Our results are consistent with previous
studies of the association of rs12979860-C/C genotype with
spontaneous clearance. We found a relationship with the highest
clearance rate among C/C Moroccan subjects (66.2%), an
intermediate clearance rate among heterozygous individuals
(23.5%), and the lowest rate in the T/T homozygous subjects
(10.3%). For spontaneous HCV clearance, Thomas et al. reported
that the IL28B rs12979860-C/T polymorphism predicted the rate
of spontaneous clearance of HCV, with the frequency of
spontaneous clearance being 53% in patients with the C/C
genotype versus 23% of patients with the T/T genotype [19].
Several larger studies reported that the rs12979860-C/C genotype
was associated with spontaneous eradication of the virus
[20,23,24,25,26,27] (Table S1). Moreover, Langhans and cowork-
ers demonstrated that high IFN-l serum levels were prevalent in
carriers of the rs12979860-C allele and associated with a
favourable outcome of HCV infection confirming the important
antiviral properties of type III interferons (IFNs) [28].
The influence of IL28B polymorphisms on the severity and
progression of liver disease remains unclear with controversial
results [13,14,15,16,29,30]. This emphasizes the necessity to
replicate these studies in ethnically diverse populations. In our
study, the frequency of patients with the rs12979860-T/T
genotype differ between mCHC and HCV-AdLD groups
(Table 3), suggesting that this polymorphism may play a role in
the progression of HCV among Moroccan patients. Actually, in
patients with advanced liver disease the frequency of the T allele
was 50%, compared to 60.4% of patients with mild liver disease.
Carriage of the T allele was found to be an independent predictor
of progression to an advanced stage, which is consistent with the
reports in other populations [13,16,29,31]. The rs12979860-T/T
genotype was previously been associated with a four-fold increase
in risk for HCC development in Italian patients, particularly
among patients infected with HCV [13]. Recently, Clark and
colleagues found that the rs12979860-T/T genotype was associ-
ated with fibrosis in patients with chronic hepatitis C [32].
Moreover, several in vitro studies and animal models demonstrated
that activation of type III IFN induces apoptosis and also that this
cytokine possesses anti-tumour activities [33]. Thus, the SNP
rs12979860 may serve as an important predictive biomarker of
liver disease and offers new insights into the biological pathways
involved in liver cirrhosis and carcinogenesis. In addition, it was
reported that the rs8099917-T/T genotype was associated with
spontaneous clearance of HCV (Table S1) and inflammatory
activity and fibrosis in patients with chronic hepatitis C in Japan.
Overall our results confirm this positive association between
rs8099917 polymorphism and progression of HCV infection
[11,34]. Overall, elucidating the mechanism by which the IL28B
polymorphisms affects the progression to cirrhosis and HCC
remains an important future challenge.
In Morocco, HCV genotype 1 is more prevalent than genotype
2. In addition, the SVR rate for individuals infected with genotype
1, is low (40–50%) and requires 12 months of therapy. Results
from our small cohort showed that patients who achieved SVR
had a higher frequency of the rs12979860-C/C genotype (75%)
compared to those carrying the T/T genotype (12.5%).
Finally, the combination of the two polymorphisms is associated
with significantly increased persistence and linked to progression
towards advanced stages of HCV-associated disease. Individuals
with rs12979860-T/T genotype and T/G or G/G of rs8099917
have an 8.27 and 4.68-fold-risk to evolve towards chronicity
respectively, and a 3.70 and 3.87 increase in risk to be affected
with an advanced liver disease.
We are, however, fully aware that the limitation of the current
study is its relatively small size and, further studies warrant the
recruitment of a larger cohort with analysis of the above
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mentioned, and additional polymorphisms and haplotypes of the
IL28B gene. These will help to clarify their role in HCV clearance
and may provide a mechanism for understanding the relationship
between IL28B and HCV infection.
In summary, our results are the first providing information
about the impact of IL28B polymorphisms on hepatitis C
outcomes and progression in the Maghrebian region. We found
that rs12979860-C/C and rs8099917-T/T genotypes showed a
strong association with resolution of HCV infection. Altogether,
our result support that IL28B polymorphisms seems to be involved
in the progression of HCV infection to cirrhosis and hepatocellular
carcinoma. This finding adds evidence to the hypothesis that the
host’s immunogenetic background modulates the progression of
liver disease in chronic hepatitis C in multiple and ethnically
diverse populations.
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